Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gamida Cell’s Bone Marrow Transplant Alternative Succeeds In Phase III

Executive Summary

The Novartis-backed company will begin a rolling submission to the US FDA for its cord blood-derived cell therapy omidubicel in Q4 based on improved engraftment versus standard cord blood. 

You may also be interested in...



Finance Watch: Moderna Capitalizes On COVID-19 Vaccine Data Value Boost

Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.

Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public

October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.

Novartis takes a 15% stake in stem cell developer and an option to buy

Novartis is to invest $35m in stem cell therapy developer Gamida Cell in exchange for a 15% stake of the Israeli firm and an option to acquire the company.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel